Therefore, one hypothesis arising from available molecular evidence in humans suggests increasingly upregulated cellular DNL in early stages of NAFLD, with hepatic AMPK and fat oxidation capacity becoming initially increased in a compensatory manner. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.